If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.50    -10.00 (-2.50%)
Bid:
385.00
Ask:
400.00
Spread: 15.00 (3.896%)
Market Cap: £187.19m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

EPA approval received

23 Apr 2018 07:00

RNS Number : 6996L
Tristel PLC
23 April 2018
 

 

Tristel plc

("Tristel" or "the Company")

 

EPA approval received

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the United States Environmental Protection Agency ("EPA") has registered its foam-based chlorine dioxide product, Duo. This registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces. The federal registration will be followed by state-by-state approvals which the Company expects to complete by the end of 2018. The Company anticipates first revenues from the United States during its 2018-19 financial year.

 

Paul Swinney, CEO of Tristel plc, comments: "We have achieved our first United States regulatory approval, and we will continue to pursue further registrations with the EPA and the Food and Drug Administration ("FDA") to build a broadly-based business in the USA.

 

"We recently announced that we have appointed Parker Laboratories Inc to manufacture Duo in its FDA approved facility in New Jersey, and to sell Duo into the ultrasound marketplace in which they have national sales coverage. We will sell our products through different channels into other clinical areas in the USA hospital market.

 

"This first United States approval is a very significant step for our Company as it enables us to access the largest healthcare market in the world. It has been our long-held ambition to be recognised as a global brand in the infection prevention industry. An active presence in the United States is necessary to achieve this ambition, and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

finnCap

Tel: 020 7220 0500

Geoff Nash/ Giles Rolls (Corporate Finance)

Alice Lane (Corporate Broking)

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKBDNQBKDPQB
Date   Source Headline
8th Nov 20103:06 pmRNSDirector Shareholding
5th Nov 201011:32 amRNSPlacing to raise £3.9million
18th Oct 20107:00 amRNSFinal Results
9th Sep 20107:00 amRNSTrading Statement
1st Jul 20107:00 amRNSDirector/PDMR Shareholding
28th Jun 201010:52 amRNSDirector/PDMR Shareholding
8th Jun 20104:01 pmRNSDirector/PDMR Shareholding
7th Jun 20105:15 pmRNSDirector/PDMR Shareholding
2nd Jun 20103:23 pmRNSDirector/PDMR Shareholding
2nd Jun 20107:00 amRNSDirectorate Change
19th Mar 20107:00 amRNSDirector/PDMR Shareholding
8th Mar 20107:00 amRNSHalf Yearly Report
25th Feb 20107:00 amRNSChange of Adviser
15th Dec 200912:03 pmRNSAGM Statement
4th Dec 20097:00 amRNSDirector/PDMR Shareholding
25th Nov 200910:35 amRNSGeneral Meeting
9th Nov 20097:00 amRNSPlacing and Notice of General Meeting
28th Oct 20099:14 amRNSDividend
13th Oct 20098:35 amRNSGrant of options
12th Oct 20097:00 amRNSFinal Results
18th Sep 20097:00 amRNSLicensing agreement
3rd Jul 200911:28 amRNSDirectors' Dealing
3rd Jul 20097:00 amRNSAcquisition and Placing
11th May 20097:00 amRNSExclusive UK distribution agreement
17th Mar 20099:35 amRNSCorrection to Record Date
16th Mar 20097:00 amRNSHalf Yearly Report
9th Mar 20097:00 amRNSNew infection control range for dental practices
8th Jan 20097:00 amRNSDirector/PDMR Shareholding
17th Dec 20087:00 amRNSAGM Statement
7th Nov 20087:00 amRNSNHS Supply Chain listing
6th Oct 20087:00 amRNSFinal Results
3rd Sep 20089:05 amRNSGrant of Patent
25th Jul 20087:00 amRNSTrading update & Notice of re
7th Jul 200810:55 amRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSGrant of Patent
23rd Jun 20087:00 amRNSSupply and Distribution Agree
28th May 200811:32 amRNSDirector/PDMR Shareholding
2nd May 20087:00 amRNSDirector/PDMR Shareholding
4th Apr 20085:04 pmRNSCorrection -Board Appointment
4th Apr 20087:01 amRNSDirector/PDMR Shareholding
3rd Apr 20087:00 amRNSBoard Appointment
27th Mar 20089:26 amRNSDirector/PDMR Shareholding
12th Mar 20081:30 pmRNSIssue of Equity
3rd Mar 20087:01 amRNSNew supply agreement
3rd Mar 20087:00 amRNSInterim Results
7th Feb 20087:00 amRNSNotice of Results
6th Feb 20081:19 pmRNSRe. Tristel Italia srl
3rd Jan 20083:29 pmRNSGrant of patent
11th Dec 200711:42 amRNSAGM Statement
5th Nov 200712:38 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.